ScoreWhy is China Resources Double-Crane Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 16.98%
- The company has been able to generate a Return on Capital Employed (avg) of 16.98% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 4.21% and Operating profit at 6.04% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 12.30% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 4.21% and Operating profit at 6.04% over the last 5 years
4
Flat results in Jun 26
- OPERATING CASH FLOW(Y) Lowest at CNY 1,525.56 MM
- ROCE(HY) Lowest at 13.89%
- DEBTORS TURNOVER RATIO(HY) Lowest at 3.21 times
5
With ROE of 13.69%, it has a fair valuation with a 1.34 Price to Book Value
- Over the past year, while the stock has generated a return of -14.48%, its profits have fallen by -7.7%
- At the current price, the company has a high dividend yield of 3
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to China Resources Double-Crane Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is China Resources Double-Crane Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
China Resources Double-Crane Pharmaceutical Co., Ltd.
-14.81%
-1.22
20.30%
China Shanghai Composite
3.23%
0.23
14.72%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.21%
EBIT Growth (5y)
6.04%
EBIT to Interest (avg)
87.63
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.91
Tax Ratio
11.50%
Dividend Payout Ratio
29.98%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.15%
ROE (avg)
12.30%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.34
EV to EBIT
9.40
EV to EBITDA
6.81
EV to Capital Employed
1.38
EV to Sales
1.38
PEG Ratio
NA
Dividend Yield
3.03%
ROCE (Latest)
14.68%
ROE (Latest)
13.69%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
INTEREST COVERAGE RATIO(Q)
Highest at 10,443.87
NET SALES(Q)
Highest at CNY 2,808.82 MM
-8What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at CNY 1,525.56 MM
ROCE(HY)
Lowest at 13.89%
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.21 times
Here's what is working for China Resources Double-Crane Pharmaceutical Co., Ltd.
Interest Coverage Ratio
Highest at 10,443.87
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales
Highest at CNY 2,808.82 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Here's what is not working for China Resources Double-Crane Pharmaceutical Co., Ltd.
Operating Cash Flow
Lowest at CNY 1,525.56 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (CNY MM)
Debtors Turnover Ratio
Lowest at 3.21 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Footer loading
